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Abstract 
Background: Streptococcus agalactiae (group B Streptococcus, GBS) is the most frequent pathogen isolated from 
neonates with invasive bacterial disease and responsible for serious infections in newborns such as pneumonia, 
septicemia and meningitis. Infection is primarily acquired vertically from mothers colonized with GBS. However, the 
prevalence and antimicrobial susceptibility pattern of GBS among pregnant women in Ethiopia are less studied.
Methods: This cross-sectional study involved 126 pregnant women at 35–37 weeks of gestation attending the ante-
natal clinic at Jimma University Hospital. Anorectal and vaginal swabs were cultured on to Todd-Hewitt broth medium 
supplemented with Gentamicin and Nalidixic acid and subsequently sub-cultured on 5 % sheep blood agar followed 
by identification of isolates based on colonial morphology, Gram stain, catalase reaction, hippurate hydrolysis and 
Christie, Atkins, Munch-Petersen (CAMP) test, and testing for their susceptibility to antimicrobial agents using the 
Kirby–Bauer method.
Results: The overall carriage rate of GBS was 19.0 % (24/126), and the rectal and vaginal carrier rates were 14.3 % 
(18/126) and 10.4 % (13/126), respectively. Concomitant vaginal and anorectal colonization was recorded in 29.2 % 
(7/24) of the women who were culture positive. All GBS isolates were susceptible to penicillin G, ampicillin, and vanco-
mycin, but a considerable proportion was resistant to clindamycin (3.2 %), erythromycin (6.5 %), ciprofloxacin (9.7 %), 
ceftriaxone (9.7 %), norfloxacin (12.9 %), cotrimoxazole (29 %), and tetracycline (45.2 %).
Conclusion: This study reveals high carriage rate of GBS among pregnant women compared to some previous 
studies in Ethiopia. However, further epidemiological investigations should be done in different parts of the country 
in order to know the actual GBS colonization rate of pregnant women and to consider the possibility of implement-
ing prophylactic treatment to prevent potential adverse maternal and neonatal outcomes. Future studies should be 
conducted to reveal serotype distributions of GBS in this community.
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Background
Streptococcus agalactiae (group B Streptococcus, GBS) is 
the most frequent pathogen isolated from neonates with 
invasive bacterial disease and responsible for serious 
infections in newborns such as pneumonia, septicemia 
and meningitis [1–3]. GBS is also associated with signif-
icant maternal peripartal disease, including bacteremia, 
endocarditis, chorioamnionitis, endometritis, urinary 
tract infections, arthritis, and responsible for serious 
bacterial illness and deaths in nonpregnant women 
with underlying diseases and in elderly adults [4–7]. 
GBS can also pass through the cervix without causing 
serious cervicitis, and cross-intact amniotic membrane 
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causing amnionitis thereby infecting the foetus within 
the uterus [4].
The lower gastrointestinal tract is considered as the 
most likely human reservoir of GBS) with a secondary 
spread to the genitourinary tract. Pregnant women who 
are GBS carriers have the potential to transmit the organ-
ism to their newborns [8]. Because vaginal colonization is 
believed to be responsible for the intrapartum exposure 
of neonates to GBS, it is important clinically to identify 
these women before delivery. In the absence of maternal 
chemoprophylaxis, up to 50 % of neonates born to colo-
nized women acquire GBS colonization and 1–2  % of 
these neonates acquire invasive disease [9]. The rate of 
GBS colonization during pregnancy varies among differ-
ent countries [10]. A review that has specifically looked at 
the prevalence of maternal colonization with GBS indi-
cated the estimated mean prevalence of GBS colonization 
was 17.9 % overall and was the highest in Africa (22.4 %) 
followed by the Americas (19.7 %) and Europe (19.0 %). 
However, Studies from Southeast Asia had the lowest 
estimated mean prevalence (11.1 %) [10]. In this review, 
significant heterogeneity was noted across and within 
regions. Differences in the timing of specimen collection 
in pregnancy, selective culture methods, and study sam-
ple size did not explain the heterogeneity [10]. In Ethio-
pia, the study by Muhammed et  al. showed that GBS 
colonization rates (20.6 %) were higher than reported by 
Lakew et al. (7.2 %) [11, 12].
Prevention guidelines for perinatal GBS disease were 
issued by Centers for Disease Control and Prevention 
(CDC) in 1996 [13]. The recommendations were revised 
in 2002, when guidelines for prevention of vertical trans-
mission, through routine screening (culture of vaginal 
and anorectal secretions between the 35th and 37th ges-
tational week) and intrapartum antibiotic prophylaxis of 
the colonized women was definitely established. Posi-
tivity for GBS colonization found during this period of 
gestation is highly predictive of the presence of GBS at a 
time of childbirth [14].
In Ethiopia, few studies have been conducted on GBS 
[11, 12, 15–17] although infant mortality is high in this 
population. Until today, there are no public health poli-
cies or strategies in Ethiopia aimed at the reduction of 
GBS neonatal infection. This study, therefore, aimed at 
determining the proportion of pregnant women colo-
nized with GBS and antimicrobial susceptibility pattern 
of the isolates at Jimma University Hospital.
Methods
Study area and participants
The present cross-sectional study included 126 preg-
nant women (from 35 to 37  weeks of gestation) who 
were attending the antenatal clinic at Jimma University 
Hospital, Jimma, Ethiopia for routine antenatal visits, 
during the period from July 2012 and December 2012. 
Jimma is located 355  km southwest of Addis Ababa. At 
this institution, it is not a common practice to determine 
colonization status, and hence, not common practice 
either, to offer prophylaxis.
Data collection
Data was collected by the attending midwifery nurse 
using a well-structured questionnaire designed to obtain 
socio-demographic data and other relevant information 
such as age, occupation, educational level and gravidity 
from participants following their written informed con-
sent and the ethical approval of the study from Jimma 
University ethics reviewed board. All consenting mothers 
with gestation age 35–37  weeks were included. Partici-
pants with a history of using antibiotic(s) 2 weeks prior to 
the study were excluded from the study.
Sample collection and laboratory procedure
Samples were collected by the attending midwifery 
nurse from the lower third of the vagina and rectum of 
all participants at 35–37 weeks of gestation using a sterile 
cotton swab and transported in Amies transport media 
with charcoal (Oxoid, UK) to the microbiology labora-
tory. Thereafter, specimens were inoculated in Todd-
Hewitt broth (Oxoid, UK), an enrichment medium for 
GBS, supplemented with 8 µg/ml gentamicin and 15 µg/
ml nalidixic acid (Biomerieux, France) to prevent the 
growth of contaminants. The broth cultures were incu-
bated at 37  °C aerobically. After 18–24  h of incubation, 
specimens were sub cultured onto 5  % sheep blood 
agar plates (Oxoid, UK) and re-incubated at the recom-
mended incubation conditions. Observation of cultures 
was conducted at 24  h and all negative culture plates 
were re-incubated for an additional 18–24  h and then 
re-examined. Suspicious GBS colonies were identified 
by colony morphology, gram stain and biochemical tests 
such as catalase, sodium hippurate hydrolysis and Chris-
tie, Atkins, Munch-Petersen (CAMP) factor positivity’s. 
Finally, antimicrobial susceptibility of all GBS isolates 
was determined by Kirby–Bauer disk diffusion method 
on Mueller–Hinton agar supplemented with 5  % sheep 
blood according to the guideline recommendations of the 
Clinical and Laboratory Standards Institute [18]. The fol-
lowing antimicrobial discs and concentrations (in brack-
ets) were used: penicillin G (10  IU), ampicillin (10  μg), 
clindamycin (2  μg), erythromycin (15  μg), vancomycin 
(30  μg), ciprofloxacin (5  μg), ceftriaxone (30  μg), cotri-
moxazole (25  μg), tetracycline (30  µg), and norfloxacin 
(10 µg). The plates were incubated at 37 °C for 20–24 h. 
The results were interpreted according to Clinical and 
Laboratory Standards Institute guidelines [18].
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Statistical analysis
All statistical calculations were done using SPSS for win-
dows version 16. Descriptive statistics were computed to 
determine the rate of GBS and other variables. The rela-
tionships between GBS colonization and various risk fac-
tors were tested using the Chi square test. A p value of 
≤0.05 was considered indicative of a statistically significant.
Results
Socio‑demographic and isolation rate
A total of 126 pregnant women were included within this 
study. The age of the women ranged from 16 to 40 years 
with mean age of 26.5  years (SD ±4.9). The majority 
(37.3  %) of the participants were between the ages of 
25–29 years. Among the 126 pregnant women screened, 
24 (19 %) were colonized with GBS (Table 1). The rectal 
and vaginal carrier rates were 18 (14.3 %) and 13 (10.3 %), 
respectively. Of the 24 carriers, GBS was isolated only 
from the rectum in 11 (45.8  %), from the vagina in 6 
(25 %), and concomitant vaginal and anorectal coloniza-
tion was recorded in 7 (29.2 %) of the women.
Sociodemographic and obstetric characteristics of 
the pregnant women are described in Table 2. No asso-
ciations were detected between risk factors and GBS 
colonization of the study subjects but the study was not 
powered to assess these.
Antimicrobial susceptibility pattern of GBS isolates
The susceptibility patterns of GBS (n = 31) isolated from 
pregnant women against ten antimicrobial agents are pre-
sented in Table 3. All GBS isolates were uniformly suscep-
tible to penicillin G, ampicillin, and vancomycin. Relatively, 
GBS showed low resistance to clindamycin (3.2  %) and 
erythromycin (6.5 %), and high resistance to cotrimoxazole 
and tetracycline with 29 and 45.2 %, respectively. Excluding 
penicillin G, ampicillin, and vancomycin, antibiogram of 
GBS isolates revealed that only 9 (29 %) isolates were sus-
ceptible to all antibiotics tested and 22 (71 %) were resistant 
to one or more antibiotics tested (data not presented).
Discussion
GBS is an important cause of infection in pregnant 
women and their newborns; however, there have been 
limited studies available in Ethiopia. Approximately one 
in five (19 %) pregnant women were colonized with GBS 
in the present study. In 11 (45.8  %) pregnant women 
GBS was isolated solely from rectal swabs. These rates 
of GBS would have been missed if only vaginal swabs 
were obtained, suggesting the importance of obtaining 
Table 1 Isolation sites and number of GBS carriers (n = 24)
Isolation site N (%)
Only rectum 11 (8.7)
Only vagina 6 (4.8)
Both vagina and rectum 7 (5.6)
Total 24 (19)
Table 2 Association between  socio-demographic, obstet-
ric factors and  GBS colonization among  pregnant women 
(n = 126)
* p value: chi squared test comparing colonized and non-colonized pregnant 
women






 15–19 7 (5.6) 3 (12.5) 4 (3.9) 0.43
 20–24 36 (28.6) 9 (37.5) 27 (26.5)
 25–29 47 (37.3) 7 (29.2) 40 (39.2)
 30–34 25 (19.8) 4 (16.7) 21 (20.6)
 35–39 9 (7.1) 1 (4.2) 8 (7.8)
 40–44 2 (1.6) 0 (0) 2 (2.0)
Educational level
 Illiterate 17 (13.5) 6 (25) 11 (10.8) 0.32
 Primary 27 (21.4) 5 (20.8) 22 (21.6)
 Secondary 58 (46) 9 (37.5) 49 (48.0)
 Post-second-
ary
24 (19) 4 (16.7) 20 (19.6)
Occupation
 House wife 81 (64.3) 20 (83.3) 61 (59.8) 0.18
 Employed 34 (27) 3 (12.5) 31 (30.4)
 Merchant 3 (2.4) 0 (0) 3 (2.9)
 Student 8 (6.3) 1 (4.2) 7 (6.9)
Gravidity
 Primigravida 38 (30.2) 5 (20.8) 33 (32.4) 0.27
 Multigravida 88 (69.8) 19 (79.2) 69 (67.6)
Total 126 (100) 24 (19) 102 (81)
Table 3 Antimicrobial susceptibility pattern of  GBS 
(n = 31) isolated from pregnant women
Antibiotics Susceptible (%) Intermediate (%) Resistant (%)
Penicillin G 100 – 0
Ampicillin 100 – 0
Vancomycin 100 – 0
Erythromycin 90.3 3.2 6.5
Ceftriaxone 90.3 – 9.7
Ciprofloxacin 90.3 – 9.7
Clindamycin 87.1 9.7 3.2
Norfloxacin 87.1 – 12.9
Cotrimoxazole 71 – 29
Tetracycline 45.2 9.7 45.2
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combined vaginal and anorectal swabs. This is consist-
ent with the findings of other investigators who recom-
mended combined vaginal and rectal swabs to maximize 
culture yield and increase detection rates [2, 19–21].
The rates of GBS colonization vary widely throughout 
the world. In Ethiopia, the study by Muhammed et  al. 
(20.6  %) [11] showed GBS colonization rate that was 
higher than that reported by Schmidt et al. (9 %) [15]. The 
overall vaginal and anorectal colonization rate of 19 % in 
our pregnant population is high compared with the study 
conducted about 27 years ago among postpartum women 
in Gondar, Ethiopia, which was 9 % [15]. The differences 
in colonization rate might be due to geographic, as well 
as differences in the study participant (pregnant versus 
postpartum).
The prevalence of GBS colonization among pregnant 
women population has been documented in several coun-
tries, including Africa, Americas, Europe and Southeast 
Asia with the estimated mean prevalence rates ranging 
from 11.1 to 22.4 %. The lower prevalence of GBS coloni-
zation among pregnant women in Southeast Asia (11.1 %) 
compared to the present study may be related to regional 
differences in race and geographic area [10, 11, 22, 23]. 
The effect of race and geographical area on the prevalence 
of GBS colonization may be related to the differences in 
nutrition, socioeconomic status, sexually transmitted dis-
eases, host immunity or sexual behavior [24, 25].
Knowledge about risk factors contributing for GBS 
colonization in pregnant women is relevant to minimize 
the morbidity, mortality associated with maternal and 
neonatal GBS infections [11]. In this study, no significant 
differences on the GBS colonization rate were detected 
when the socio-demographic and obstetric variables were 
considered. Unlike to our result, other studies showed 
that maternal age, education, gravidity and occupation 
have been observed as risk factors for GBS colonization 
among pregnant women [25–28]. However, there have 
been marked inconsistencies in studies that report the 
relationship between these factors and GBS colonization. 
For example, some studies showed that the prevalence of 
GBS increased with age [29], while others found it more 
with a younger age group [30, 31]. The findings from this 
study might be due to the small number of study subjects 
underpowered to find the possible risk factors, and these 
indicate the need for future large- scale study.
The universal prenatal screening and the risk-based 
approach are commonly used strategies proposed by the 
CDC in order to decrease the incidence of early-onset 
GBS neonatal infection [13, 14]. Before deciding which of 
these two strategies is to follow, a prevalence of GBS in 
the population has to be investigated (i.e., does the pro-
portion of colonized pregnant women) with the identifi-
cation of maternal risk factors.
In this study, all GBS isolates were uniformly sensitive 
to penicillin, ampicillin and vancomycin, which is con-
sistent with previous reports recommending these anti-
biotics as the agent of choice for GBS prophylaxis [2, 11, 
18, 29]. The proportion of isolates with in vitro resistance 
to clindamycin and erythromycin, which are considered 
first-line prophylaxis for those with an allergy to penicil-
lin, has progressively increased since 1996 [14]. The prev-
alence of resistance among GBS isolates ranged from 7 to 
40 % for erythromycin and from 3 to 26.4 % for clindamy-
cin and might be associated with certain serotypes [19, 
32, 33]. A relatively high level of resistance to tetracycline 
and cotrimoxazole in this study might be attributed to 
the wide and indiscriminate use of antimicrobial drugs. 
Since in Ethiopia, members from the public easily move 
into pharmacy shops to buy antibiotics without prescrip-
tion (personal communication with drug vendors). This 
use of antibiotics is indiscriminate and might account for 
the high resistance rates observed.
Conclusions and recommendations
This study reveals that one-fifth of pregnant women har-
bored GBS, which may pose a risk for the newborns. 
Therefore, further large-scale studies and data on the 
prevalence of GBS neonatal disease, preventative meas-
ures, and outcome of infected infants are imperative in 
this community to allow the preventive strategy. The study 
also indicates uniform susceptibility of GBS isolates from 
pregnant women to penicillin G, ampicillin and vancomy-
cin. Even though no standard-of–care practices for GBS 
prevention in this setting, tetracycline and cotrimoxazole 
should not be used for GBS prevention. Future studies 
should be conducted to reveal serotype distributions of 
GBS in this community since monitoring of regional vari-
ations in serotype distribution is required to develop and 
implement effective vaccine for prevention of GBS disease.
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